8-K: Indaptus Therapeutics Secures $20 Million Standby Equity Purchase Agreement with YA II PN, LTD.

Indaptus Therapeutics enters into a Standby Equity Purchase Agreement with YA II PN, LTD. for up to $20 million in funding over the next 36 months.

Summary

• Indaptus Therapeutics, Inc. has entered into a Standby Equity Purchase Agreement (SEPA) with YA II PN, LTD. (Yorkville) on February 12, 2025.
• The agreement allows Indaptus to sell up to $20.0 million of its common stock to Yorkville over a 36-month period.
• Indaptus has the right, but not the obligation, to sell shares to Yorkville.
• The purchase price will be 97% of the lowest of the three daily volume-weighted average prices (VWAPs) during a three-day trading period after Indaptus notifies Yorkville of its intent to sell shares.
• As consideration for Yorkville's commitment, Indaptus will issue 305,960 shares of common stock (Commitment Shares) and pay a $25,000 structuring fee to Yorkville.
• The company may not issue or sell to the Investor shares of Common Stock in excess of 2,823,244 shares, which is 19.99% of the shares of Common Stock outstanding immediately prior to the execution of the SEPA, unless stockholder approval is obtained or the average price of all applicable sales of Common Stock under the SEPA equals or exceeds $0.81722 per share.
• Yorkville's obligation to purchase shares is subject to conditions, including the SEC declaring effective a registration statement for the Commitment Shares and Advance Shares.
• Indaptus terminated its previous purchase agreement with Lincoln Park Capital Fund, LLC, effective February 12, 2025.
• The securities will be issued and sold to Yorkville under exemptions from registration requirements of the Securities Act of 1933.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While the agreement provides access to capital, it also carries the risk of dilution and is subject to market conditions. The terms are fairly standard for this type of financing.

Positives

• Indaptus gains access to a potential $20 million in funding over the next three years.
• The agreement provides flexibility, as Indaptus is not obligated to sell shares if it doesn't need the capital.
• The structuring fee is relatively small at $25,000.
• The company retains control over the timing and amount of shares sold, subject to certain limitations.

Negatives

• The purchase price is discounted at 97% of the VWAP, which could dilute existing shareholders.
• Issuing 305,960 shares upfront dilutes existing shareholders immediately.
• The Exchange Cap limits the number of shares that can be issued without stockholder approval or a higher average price.
• The company may not issue or sell to the Investor shares of Common Stock in excess of 2,823,244 shares, which is 19.99% of the shares of Common Stock outstanding immediately prior to the execution of the SEPA, unless stockholder approval is obtained or the average price of all applicable sales of Common Stock under the SEPA equals or exceeds $0.81722 per share.

Risks

• The agreement is subject to market conditions and Yorkville's ability to purchase shares.
• The registration statement must be declared effective by the SEC, which is not guaranteed.
• The company's stock price could be negatively impacted by the potential for dilution.
• There is a risk that Indaptus may not be able to utilize the full $20 million commitment if it cannot meet the conditions of the agreement.
• The company may not issue or sell to the Investor shares of Common Stock in excess of 2,823,244 shares, which is 19.99% of the shares of Common Stock outstanding immediately prior to the execution of the SEPA, unless stockholder approval is obtained or the average price of all applicable sales of Common Stock under the SEPA equals or exceeds $0.81722 per share.

Future Outlook

Indaptus Therapeutics intends to use the proceeds from the sale of shares under the SEPA for general corporate purposes, as will be detailed in a future prospectus.

Industry Context

Standby equity purchase agreements are a relatively common financing tool for small-cap and micro-cap companies, providing access to capital but also carrying the risk of dilution. The terms of this agreement appear fairly standard for this type of arrangement.

Comparison to Industry Standards

• Similar agreements often involve discounts to market price, with 3% being a typical discount.
• The 19.99% Exchange Cap is a common feature to avoid requiring shareholder approval under Nasdaq rules.
• Comparable companies that have used similar financing structures include [hypothetical company A] and [hypothetical company B], although the specific terms vary based on the company's financial situation and market conditions.

Stakeholder Impact

• Shareholders may experience dilution if Indaptus sells a significant number of shares under the agreement.
• The company's employees and operations could benefit from the additional capital.
• The agreement could provide Indaptus with greater financial flexibility to pursue its business strategy.

Next Steps

• Indaptus needs to file a registration statement with the SEC to cover the shares to be issued under the agreement.
• The company will need to monitor its stock price and trading volume to determine the optimal timing for selling shares to Yorkville.
• Indaptus will need to comply with all terms and conditions of the agreement to maintain access to the funding.

Key Dates